ABS37: Add-on omalizumab improves asthma control across multiple measures of response in patients with severe persistent allergic (IgE-mediated) asthma | Zendy

AI Assistant Blog Pricing

ABS37: Add-on omalizumab improves asthma control across multiple measures of response in patients with severe persistent allergic (IgE-mediated) asthma

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.